Pharnext to showcase PLEOTHERAPY™ R&D platform at the Global Orphan Drug Conference
Pharnext confirms its continued eligibility to the PEA-PME (only available in French)
Pharnext reports financial results for Year-End 2017
Pharnext successfully raises €16 million via private placement
Pharnext to present a corporate overview at the H.C. Wainwright Annual Global Life Sciences Conference
Pharnext to attend Shareholders meetings in Bordeaux and Lyon (only in French)
Pharnext to attend Shareholders meeting in Paris (only in French)
PXT3003: Status of ongoing Phase 3 trial to be featured at the Francophone Peripheral Nerve Society conference
Philippe Chambon joins Pharnext’s Board of Directors
PXT3003: Successful intermediate analyses for Phase 3 trial in CMT1A
Pharnext to Attend November Investor Conferences
PXT864: new synergy data to be presented at CTAD in Boston, USA
PXT3003: Featured at the Hereditary Neuropathy Foundation (HNF) Annual Patient-Centered Summit
Pharnext announces first half 2017 results
Pharnext to present at 4th International Neurotech Investing and Partnering Conference
Pharnext amends the protocol of the international pivotal Phase 3 trials of PXT3003 for CMT1A
Pharnext to Present at 7th Annual CEC Capital Summit
PXT3003: Featured at the AANEM 2017 Annual Meeting
PXT3003: DSMB recommends continuing the ongoing Phase 3 Trial of PXT3003 for CMT1A
Pharnext to present at Rodman & Renshaw 19th Annual Global Investment Conference
Pharnext to hold its first satellite symposium on CMT1A at Neuromuscular Days in Marseille
PXT864: Data presented at the Alzheimer's Association International Conference 2017
PXT3003: Status of ongoing Phase 3 trial to be featured at the 2017 Peripheral Nerve Society Meeting
Pharnext to showcase PLEOTHERAPY™ platform at Drug Repositioning, Repurposing and Rescue Conference
Strategic partnership with Tasly, a leading Chinese pharmaceutical group
Pharnext reports year end 2016 financial results
Pharnext confirms its continued eligibility to the PEA-PME
Reclassification of historical investor’s shares - Strengthening the position of core shareholders
PXT864: New synergy data presented at AD/PD™ 2017 Conference in Vienna, Austria
PXT3003: initiation of Phase 3 extension study PLEO-CMT-FU for CMT1A
Page 1 of 3
